Raphas Co. Ltd
Raphas Co., Ltd. manufactures and sells biodegradable microneedles in Korea. The company offers skin care, medical device, whitening care, and wrinkle care under the Acropass brand; and health food product under the FitKong brand. It also supplies double-layer microneedle manufacturing technology; and provides original development manufacturing, and contract development and manufacturing organiza… Read more
Raphas Co. Ltd (214260) - Net Assets
Latest net assets as of September 2025: ₩32.62 Billion KRW
Based on the latest financial reports, Raphas Co. Ltd (214260) has net assets worth ₩32.62 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩82.76 Billion) and total liabilities (₩50.14 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩32.62 Billion |
| % of Total Assets | 39.41% |
| Annual Growth Rate | 3.08% |
| 5-Year Change | -33.54% |
| 10-Year Change | N/A |
| Growth Volatility | 52.95 |
Raphas Co. Ltd - Net Assets Trend (2017–2024)
This chart illustrates how Raphas Co. Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Raphas Co. Ltd (2017–2024)
The table below shows the annual net assets of Raphas Co. Ltd from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩29.36 Billion | -9.12% |
| 2023-12-31 | ₩32.31 Billion | -21.06% |
| 2022-12-31 | ₩40.93 Billion | -21.83% |
| 2021-12-31 | ₩52.36 Billion | +18.51% |
| 2020-12-31 | ₩44.18 Billion | -7.63% |
| 2019-12-31 | ₩47.83 Billion | +137.59% |
| 2018-12-31 | ₩20.13 Billion | -15.21% |
| 2017-12-31 | ₩23.74 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Raphas Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 32695627000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩4.46 Billion | 15.19% |
| Other Components | ₩25.68 Billion | 87.46% |
| Total Equity | ₩29.36 Billion | 100.00% |
Raphas Co. Ltd Competitors by Market Cap
The table below lists competitors of Raphas Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Neuronetics Inc
NASDAQ:STIM
|
$47.34 Million |
|
Deoleo S.A
PINK:SOSCF
|
$47.35 Million |
|
Cayson Acquisition Corp
NASDAQ:CAPNU
|
$47.36 Million |
|
Reeder Teknoloji Sanayi ve Ticaret Anonim Sirketi
IS:REEDR
|
$47.36 Million |
|
Byuksan Corp
KO:007210
|
$47.32 Million |
|
Woosu AMS Co.Ltd
KQ:066590
|
$47.31 Million |
|
Jaiprakash Associates Limited
NSE:JPASSOCIAT
|
$47.30 Million |
|
Mawson Finland LImited
V:MFL
|
$47.29 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Raphas Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 29,541,467,620 to 29,362,408,780, a change of -179,058,840 (-0.6%).
- Net loss of 4,771,518,570 reduced equity.
- Share repurchases of 2,707,221,670 reduced equity.
- New share issuances of 293,400,000 increased equity.
- Other factors increased equity by 7,006,281,400.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-4.77 Billion | -16.25% |
| Share Repurchases | ₩2.71 Billion | -9.22% |
| Share Issuances | ₩293.40 Million | +1.0% |
| Other Changes | ₩7.01 Billion | +23.86% |
| Total Change | ₩- | -0.61% |
Book Value vs Market Value Analysis
This analysis compares Raphas Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.00x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ₩3523.07 | ₩10490.00 | x |
| 2018-12-31 | ₩2987.35 | ₩10490.00 | x |
| 2019-12-31 | ₩5733.04 | ₩10490.00 | x |
| 2020-12-31 | ₩5248.46 | ₩10490.00 | x |
| 2021-12-31 | ₩6092.15 | ₩10490.00 | x |
| 2022-12-31 | ₩4839.82 | ₩10490.00 | x |
| 2023-12-31 | ₩3445.48 | ₩10490.00 | x |
| 2024-12-31 | ₩3492.01 | ₩10490.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Raphas Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -16.25%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -17.53%
- • Asset Turnover: 0.36x
- • Equity Multiplier: 2.59x
- Recent ROE (-16.25%) is below the historical average (-13.66%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -22.76% | -77.90% | 0.20x | 1.47x | ₩-7.78 Billion |
| 2018 | -19.09% | -38.23% | 0.29x | 1.71x | ₩-5.86 Billion |
| 2019 | 0.26% | 0.69% | 0.29x | 1.31x | ₩-4.66 Billion |
| 2020 | -10.28% | -25.42% | 0.30x | 1.35x | ₩-8.96 Billion |
| 2021 | 9.42% | 24.24% | 0.21x | 1.87x | ₩-305.77 Million |
| 2022 | -20.79% | -36.00% | 0.25x | 2.35x | ₩-12.60 Billion |
| 2023 | -29.80% | -31.52% | 0.28x | 3.40x | ₩-11.76 Billion |
| 2024 | -16.25% | -17.53% | 0.36x | 2.59x | ₩-7.71 Billion |
Industry Comparison
This section compares Raphas Co. Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $209,689,906,881
- Average return on equity (ROE) among peers: -10.47%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Raphas Co. Ltd (214260) | ₩32.62 Billion | -22.76% | 1.54x | $47.33 Million |
| ORIENTBIO Inc. (002630) | $67.35 Billion | -2.60% | 1.21x | $28.10 Million |
| Green Cross (005250) | $282.15 Billion | 18.83% | 0.53x | $228.88 Million |
| Green Cross Holdings Preference Shares (005257) | $1.44 Trillion | 3.01% | 0.78x | $410.72 Million |
| Pharmicell (005690) | $9.90 Billion | -119.73% | 2.00x | $438.14 Million |
| GeneOne Life Science Inc (011000) | $39.74 Billion | 0.00% | 0.49x | $53.78 Million |
| HLB Co. Ltd (028300) | $77.24 Billion | -21.40% | 1.44x | $4.11 Billion |
| Daesung Microbiological Labs. Co. Ltd (036480) | $25.09 Billion | 18.13% | 0.29x | $14.92 Million |
| Seoulin Bioscience Co.Ltd (038070) | $51.49 Billion | 4.00% | 0.38x | $27.72 Million |
| Hyundai Bioscience Co. Ltd (048410) | $39.30 Billion | 0.00% | 0.56x | $899.28 Million |
| iNtRON Biotechnology Inc (048530) | $64.96 Billion | -4.91% | 0.37x | $83.99 Million |